FDA oversight of nanotechnology-based products could be lacking

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Concerns have arisen regarding whether the FDA is prepared for the coming onslaught of products — such as new drugs, medical devices — that make use of nanotechnology, United Press International reports. The biggest problem the agency must confront is one of funding, which prevents it from developing proper resources for regulating new technology such as this, Michael Taylor, a former deputy commissioner for policy at the FDA, and professor at the University of Maryland School of Medicine, told UPI. This shortfall in resources could cause important technologies that make use of nanotechnology to be delayed from entering the market, or blocked entirely. Taylor also questions whether the FDA has the legal authority to gain some of the information necessary to approve nanotechnology-based products or the authority to effectively track post-market performance of them.

More: http://www.upi.com/HealthBusiness/view.php?StoryID=20061005-045707-1867r